E-cigarettes as a Harm Reduction Strategy

Smoking Clinical Trial

Official title: E-cigarettes for Harm Reduction in Adults With Opioid Use Disorder

Status Recruiting

Clinical Trial Summary

E-cigarettes have emerged as an effective strategy for replacing cigarettes among smokers from the general population, but there is a dearth of studies investigating their utility in replacing cigarettes among smokers with opioid use disorder (OUD). This study aims to evaluate the feasibility and acceptability of implementing a cigarette harm reduction intervention involving e-cigarettes in office-based buprenorphine clinics.

Clinical Trial Description

Between 84-94% of individuals with opioid use disorder (OUD) smoke cigarettes, a rate six times higher than the general US adult population. Despite the majority of smokers with OUD expressing motivation to quit, cessation rates remain extremely low, even with evidence-based medications. E-cigarettes have emerged as a harm reduction strategy for smokers unable or unwilling to quit. Research on the effectiveness of e-cigarettes for smoking reduction among individuals with OUD on buprenorphine/methadone maintenance treatment is scarce but promising. This study is an open-label single-arm clinical trial testing the use of e-cigarettes as a harm reduction strategy among smokers with OUD on buprenorphine in a real-world setting. ;

Related Conditions & MeSH terms

• Smoking

• NCT number: NCT06277271
• Study type: Interventional
• Source: Prisma Health-Upstate
• Contact: Irene Pericot-Valverde
• Phone: 8549998005
• Email: iperico@clemson.edu
• Status: Recruiting
• Phase: N/A
• Start date: June 20, 2023
• Completion date: March 20, 2024